Can women use medical abortion without medical supervision?

References

• B. Winikoff. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: A comparative trial of mifepristone-misoprostol versus surgical abortion. American Journal of Obstetrics and Gynecology. 176(2): 1997; 431–437.
   PubMed Web of Science ®Google Scholar
• B. Winikoff. The acceptability of medical abortion in China, Cuba and India. International Family Planning Perspectives. 1997. (forthcoming).
   Google Scholar
• J.M. Hicks. Reliability of home pregnancytest kits in the hands of lay persons. New England Journal of Medicine. 320(5): 1989; 320–321. (letter).
   PubMed Web of Science ®Google Scholar
• R. Hatcher. Contraceptive Technology. 1994; Irvington Publishers Press: New York.
   Google Scholar
• Patient label, Fact Plus® One Step pregnancy test. Advanced Care Products, Ortho Pharmaceutical Corporation, Johnson and Johnson. Raritan NJ.
   Google Scholar
• Patient label, Fact Plus® One Step pregnancy test. Advanced Care Products, Ortho Pharmaceutical Corporation, Johnson and Johnson. Raritan NJ.
   Google Scholar
• World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. Human Reproduction. 10(2): 1995; 308–314.
   Web of Science ®Google Scholar
• A. Glasier. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. New England Journal of Medicine. 327(15): 1992; 1041–1044.
   PubMed Web of Science ®Google Scholar
• A.M.C. Webb. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. British Medical Journal. 305(6859): 1992; 927–931.
   PubMed Web of Science ®Google Scholar
• D.A. Grimes. A randomized clinical trial of mifepristone (RU486) for induction of delayed menses: efficacy and acceptability. Contraception. 46(1): 1992; 1–10.
   Web of Science ®Google Scholar
• C. Dubois. Contragestion with late luteal administration of RU 486 (Mifepristone). Fertility and Sterility. 50(4): 1988; 593–596.
   Web of Science ®Google Scholar
• E. Aubény. Termination of early pregnancy (up to and after 63 days of amenorrhea) with mifepristone (RU 486) and increasing doses of misoprostol. International Journal of Fertility. 40(Supplement 2): 1995; 85–91.
   Google Scholar
• P.Y. Robillard. Validity of postnatal assessments of gestational age in low birthweight infants from a Caribbean community. Journal of Perinatology. 12(2): 1992; 115–119.
   Google Scholar
• S.M. Sayers. An evaluation of three methods used to assess the gestational age of aboriginal neonates. Journal of Paediatric Child Health. 28(4): 1992; 312–317.
   Web of Science ®Google Scholar
• U. Waldenstrom. Sonographic dating of pregnancies among women with menstrual irregularities. Acta Obstetricia Gynecologica Scandinavica. 70(1): 1991; 17–20.
   Web of Science ®Google Scholar
• The other contra-indications are IUD in place, chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, misoprostol or other prostaglandin, and haemorrhagic disorders or concurrent anticoagulant therapy.
   Google Scholar
• B. Couzinet. Termination of early pregnancy by the progesterone antagonist RU 486 (mifepristone). New England Journal of Medicine. 315(25): 1986; 1565–1570.
   Web of Science ®Google Scholar
• D.A. Grimes. Early abortion with a single dose of the antiprogestin RU-486. American Journal of Obstetrics & Gynecology. 158(6): 1988; 1307–1312.
   Web of Science ®Google Scholar
• T.B. Koopersmith. The use of misoprostol for termination of early pregnancy. Contraception. 53(4): 1996; 237–242.
   Web of Science ®Google Scholar
• A. Bugalho. Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. Contraception. 53(4): 1996; 243–246.
   Web of Science ®Google Scholar
• J. Bangou. RU 486/Misoprostol (3/2+1) in Guadeloupe. Paper presented to 39th Annual Commonwealth Caribbean Medical Research Council Meeting, Jamaica, April 21–23 1994,
   Google Scholar
• E.A. Schaff. Vaginal misoprostol adminstered at home after mifepristone (RU486) for abortion. Journal of Family Practice. 44(4): 1997; 353–360.
   PubMed Web of Science ®Google Scholar
• E.A. Schaff. Combined methotrexate and misoprostol for early induced abortion. Archives of Family Medicine. 4: 1995; 774–779.
   PubMedGoogle Scholar
• M.D. Creinin. A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. American Journal of Obstetrics & Gynecology. 173(5): 1995; 1578–1584.
   PubMed Web of Science ®Google Scholar
• E.R. Wiebe. Abortion induced with methotrexate and misoprostol. Canadian Medical Association Journal. 154(2): 1996; 165–170.
   Web of Science ®Google Scholar
• Y.F. Chan. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception. 47(1): 1993; 85–95.
   Web of Science ®Google Scholar
• M.W. Rodger. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analogue (gemeprost). Contraception. 40(4): 1989; 439–447.
   Web of Science ®Google Scholar
• C. Marshall. Blood Donors Needed. 1996. Internet addresswww.mhs.milford.k12. nh.us/spartan/april/april-6.htm1
   Google Scholar
• Y.F. Chan. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception. 47: 1993; 85–95.
   Web of Science ®Google Scholar
• D.R. Urquhart. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK multicentre study — final results. Contraception. 55(1): 1997; 1–5.
   Web of Science ®Google Scholar